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Summary Twenty patients with secondary liver tumours, predominantly from colorectal carcinoma, were
treated with oral urea at a daily dose of 8gm-2. Treatment was well tolerated without side-effects. No
objective responses were seen. It is concluded that oral urea is ineffective in the treatment of liver metastases
from colorectal cancer.
Recent reports have suggested that urea may be a novel and
effective anti-cancer drug. The cytotoxic action of urea has
been demonstrated in Hela cells in suspension cultures
(Glinos et al., 1983). The local injection and application of
urea have been reported to induce remissions of basal cell
and squamous cell carcinomas of the skin (Danopoulos &
Danopoulou, 1974a), and of carcinomas of the cervix
(Gandhi et al., 1977). Danopoulos and Danopoulou (1974b,
1975, 1981) have also described the use of urea to treat
malignancies involving the liver. Patients with hepatoma and
liver secondaries from cancers of the colon, stomach, breast
and other organs were treated with oral urea at a total dose
of 12-15g daily. In patients with hepatoma, 14 of 18
patients (77%) responded, 33% achieving a complete
remission. In patients with liver secondaries, 16 of 21 (76%)
responded, the majority having a complete response. It has
been postulated that urea is delivered to the liver in high
concentrations when given orally, via absorption into the
portal venous system (Danopoulos & Danopoulou, 1981).
There is no effective systemic therapy for such liver
tumours and these reported results are therefore surprising.
A phase II study of oral urea was therefore conducted in
patients with liver metastases, predominantly from colorectal
cancer.
Materials and methods
Patients were entered into the study if they had liver
metastases from a tumour for which no effective therapy was
available and if there was no evidence of tumour outside the
liver. All patients had a Karnofsky performance score of
>50% and all had measurable disease. Only focal liver
lesions sufficiently defined to obtain measurements in at least
2, preferably 3, planes were used to assess disease, and
ultrasonography was employed in all but one patient who
had computed tomography (CT).
Twenty patients were entered into the study, 10 female
and 10 male. The age range was 47-77 years with a mean of
61 years. The primary cancer was colorectal in 17 patients, a
melanoma in one patient and 2 patients had adeno-
carcinomas of unknown origin. All patients were previously
untreated except for 3 with colorectal cancer who had had 5-
fluorouracil.
Urea was administered at a total dose of 8 gm-2 in
divided doses 4 times daily, and was continued until disease
progression occurred. In order to disguise the bitter taste of
urea, a 20% weight/volume solution of urea was made in
blackcurrant syrup. Using a specific enzyme assay for urea
and thin layer chromatography, this solution of urea was
found to be stable at room temperature for at least a month.
Prescriptions for urea were renewed monthly at each clinic
visit.
Ultrasound liver scans were performed by the same radio-
logist (JAWW) using a Phillips B7100 static scanner with a
3.5 MHz transducer and Kretz Combison 100 realtime
scanner with either a 2.5 or 4.0MHz transducer up to July
1985. A Diasonics DRF 100 realtime scanner with a
3.5 MHz transducer was used after this time. Scans were
repeated every 3 months or at any time before this if the
patient had clinical evidence of disease progression.
Response was assessed according to standard WHO criteria
(Miller et al., 1981).
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Figure 1 Liver ultrasound scans demonstrating progression of
an echogenic colon carcinoma metastasis on urea treatment: (a)
start of urea: 6cm diameter; (b) 11 months later: 8cm diameter;
(c) 22 months later: 10cm diameter. (All images to same scale.)
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Results
All 20 patients were evaluable for tumour response. Eighteen
had progressive disease on their liver ultrasound or CT scans
(see Figure 1). One patient relapsed in the pelvis with stable
liver disease, and one stopped treatment after 6 weeks
because of progressive disease symptoms but had stable liver
disease on ultrasound. In addition, 9 patients had significant
increases in levels of carcino-embryonic antigen and there
was no evidence of improvement in liver function tests in
any patient. Fifteen patients completed 3 months of urea
treatment, 3 had 5-7 months and one patient was treated for
3 years, although he progressed after 11 months.
All patients tolerated the urea in blackcurrant syrup
without toxicity and found its taste acceptable. Plasma urea
concentrations were not affected by the treatment.
Discussion
The conventional treatment for liver secondaries from
colorectal cancer is with 5-fluorouracil which has a response
rate of only about 15% (Moertel, 1978). Such therapy has
significant toxicity and there is little evidence that it prolongs
survival.
The reports by Danopoulos and Danopoulou (1974b,
1975, 1981) of the efficacy of urea in secondary liver cancer
were therefore of great interest, especially as urea treatment
is cheap, non-toxic and free of side-effects. In their studies,
patients were treated with urea if less than one third of the
liver parenchyma was estimated at laparotomy to be
involved, and were excluded if they had ascites or a bilirubin
greater than 85jimoll-1. Response to therapy was usually
evident after 2-3 months of treatment, and patients were
mostly assessed on disease symptoms and clinical assessment
of their liver size, with only a minority of patients having
liver isotope scans. Despite the lack of radiological
confirmation of response in these patients with liver
secondaries, the results of therapy were remarkable with 14
of 21 having complete and 2 of 21 partial resolution of
hepatomegaly.
Urea in the current study was administered in an identical
dose and manner to that of Danopoulos and Danopoulou
(1975, 1981). Tumour response was objectively assessed by
serial liver ultrasound scans, a method of tumour detection
that has been demonstrated to be reliable (Lamb & Taylor,
1982) and more specific than nuclear medicine scanning
(Grossman et al., 1977; Sullivan et al., 1978). The lack of
any response is disappointing but these results are in
agreement with two other studies (Ruge-Andersen et al.,
1981; Hooper et al., 1984) in which a total of 19 patients
with colorectal cancer were treated without response.
This study has therefore failed to confirm that oral urea
therapy has activity in liver secondaries from colorectal
cancer.
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